Alentis is discovering and developing first-in-class medications to treat advanced liver diseases such as fibrosis, cirrhosis and hepatocellular carcinoma, which have high unmet medical needs

Alentis lead project is a mAb targeting a novel MoA, called Claudin-1, that is central in advanced liver fibrosis and that may reverse the course of disease progression. In addition there is a suggested role of Claudin-1 in liver cancer

Alentis is expanding its pipeline using its proprietary discovery platform that enables the identification of novel targets and biomarkers as well as revealing new drug candidates

Alentis has in-licensed IP, which is the result of more than a decade of research excellence, from University Strasbourg / INSERM

Alentis is a VC-funded start-up and based in Basel and Strasbourg